Loading...
•
Dec 31, 2023
ICU Medical Q4 2023 Earnings Report
ICU Medical's fourth quarter results were generally in line with expectations.
Key Takeaways
ICU Medical reported Q4 2023 revenue of $587.9 million, a slight increase from $578.0 million in the same period last year. The company's GAAP net loss was $(17.1) million, or $(0.71) per diluted share, compared to a net loss of $(15.5) million, or $(0.65) per diluted share, for the fourth quarter of 2022. Adjusted diluted earnings per share for the fourth quarter of 2023 was $1.57 as compared to $1.60 for the fourth quarter of 2022. Adjusted EBITDA was $86.3 million for the fourth quarter of 2023 as compared to $96.4 million for the fourth quarter of 2022.
Q4 2023 revenue reached $587.9 million, slightly up from $578.0 million in the prior year.
GAAP gross profit was $171.6 million, compared to $174.9 million in the same period last year.
GAAP net loss amounted to $(17.1) million, or $(0.71) per diluted share.
Adjusted diluted earnings per share stood at $1.57, compared to $1.60 in the prior year.
Revenue by Segment
Forward Guidance
For Fiscal Year 2024 the Company estimates GAAP net loss to be in the range of $(88) to $(71) and GAAP diluted loss per share estimated to be in the range of $(3.57) to $(2.87). For the Fiscal Year 2024, the Company expects adjusted EBITDA to be in the range of $330 million to $370 million, and adjusted diluted EPS to be in the range of $4.40 to $5.10.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...